## [ERRATA]

## RISK AND RESPONSIBILITY: THE ROLES OF FDA AND PHARMACEUTICAL COMPANIES IN ENSUR-ING THE SAFETY OF APPROVED DRUGS, LIKE VIOXX

## **HEARING**

BEFORE THE

# COMMITTEE ON GOVERNMENT REFORM HOUSE OF REPRESENTATIVES

ONE HUNDRED NINTH CONGRESS

FIRST SESSION

MAY 5, 2005

Serial No. 109-27

Printed for the use of the Committee on Government Reform



Available via the World Wide Web: http://www.gpo.gov/congress/house http://www.house.gov/reform

U.S. GOVERNMENT PRINTING OFFICE

22–684 PDF

WASHINGTON: 2005

For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001

#### COMMITTEE ON GOVERNMENT REFORM

TOM DAVIS, Virginia, Chairman

CHRISTOPHER SHAYS, Connecticut DAN BURTON, Indiana ILEANA ROS-LEHTINEN, Florida JOHN M. McHUGH, New York JOHN L. MICA, Florida GIL GUTKNECHT, Minnesota MARK E. SOUDER, Indiana STEVEN C. LATOURETTE, Ohio TODD RUSSELL PLATTS, Pennsylvania CHRIS CANNON, Utah JOHN J. DUNCAN, JR., Tennessee CANDICE S. MILLER, Michigan MICHAEL E. TURNER, Ohio DARRELL E. ISSA, California GINNY BROWN-WAITE, Florida JON C. PORTER, Nevada KENNY MARCHANT, Texas LYNN A. WESTMORELAND, Georgia PATRICK T. McHENRY, North Carolina CHARLES W. DENT, Pennsylvania VIRGINIA FOXX, North Carolina

HENRY A. WAXMAN, California
TOM LANTOS, California
MAJOR R. OWENS, New York
EDOLPHUS TOWNS, New York
PAUL E. KANJORSKI, Pennsylvania
CAROLYN B. MALONEY, New York
ELIJAH E. CUMMINGS, Maryland
DENNIS J. KUCINICH, Ohio
DANNY K. DAVIS, Illinois
WM. LACY CLAY, Missouri
DIANE E. WATSON, California
STEPHEN F. LYNCH, Massachusetts
CHRIS VAN HOLLEN, Maryland
LINDA T. SANCHEZ, California
C.A. DUTCH RUPPERSBERGER, Maryland
BRIAN HIGGINS, New York
ELEANOR HOLMES NORTON, District of
Columbia

BERNARD SANDERS, Vermont (Independent)

Melissa Wojciak, Staff Director

David Marin, Deputy Staff Director/Communications Director

Rob Borden, Parliamentarian

Teresa Austin, Chief Clerk

Phil Barnett, Minority Chief of Staff/Chief Counsel

### **ERRATA**

The prepared statement of Hon. Charles W. Dent was not included in the hearing record and appears below.
[The prepared statement of Hon. Charles W. Dent follows:]

Statement for FDA/Vioxx Hearing from Congressman Dent:

Thank you, Chairman Davis, for holding this very important hearing on the roles of the FDA and pharmaceutical companies in ensuring the safety of approved drugs.

It is extremely important that prescription drugs are safe and effective. I am encouraged by the FDA's drug safety initiative of the creation of the Drug Safety Oversight Board (DSB). The DSB will provide oversight and advice to the Director of FDA's Center for Drug Evaluation and Research (CDER) on the management of important drug safety issues and will manage the flow of emerging safety information through FDA's recently proposed Drug Watch Web site to health care professionals and patients.

While I am concerned about the possible underestimation of the risks involved in the long-term use of any and all drugs, I applaud Merck's voluntary withdraw, independent of FDA input, of the drug Vioxx from the market, in September 2004. While the subsequent studies of the drugs Bextra and Celebrex were also found to have links to cardiovascular risks, earlier this year (February 2005) the FDA Advisory Committee endorsed the continued marketing of Bextra, Celebrex, and Vioxx, finding the benefits of the drugs outweighed the risks, in that Vioxx is considered safer for the stomach than aspirin and other anti-inflammatory drugs. Several months later, in April 2005, upon FDA review of the Advisory Committee's recommendations, the FDA asked to withdraw Bextra from the market and requested the inclusion of a "black box" warning regarding cardiovascular risks on Celebrex labeling. However, it made no official ruling regarding Vioxx because of Merck's voluntary removal.

It is important that we work to restore confidence in our nation's drug supply. The FDA must facilitate <u>early</u> and accurate information regarding the risks and benefits of prescription drugs to health care practitioners and patients. The FDA must communicate to the public the latest information regarding prescription drugs so that the patient, along with his or her physician, can make the best possible treatment decisions. We must also be sure that drug companies are not burying information about a drug's safety or effectiveness.

 $\bigcirc$